TIL
Instil Bio Inc.
NASDAQ: TIL · HEALTHCARE · BIOTECHNOLOGY
$7.85
-2.85% today
Updated 2026-04-29
Market cap
$54.80M
P/E ratio
—
P/S ratio
54,248.82x
EPS (TTM)
$-10.70
Dividend yield
—
52W range
$6 – $43
Volume
0.0M
Instil Bio Inc. (TIL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $138000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | -100.0% | — | — | — | — |
| Cost of revenue | $20000.00 | — | $2.75M | $5.99M | $4.76M | $3.61M | $534000.00 |
| Gross profit | $-20000.00 | $138000.00 | $-2.75M | $-5.99M | $-4.76M | $-3.61M | $-534000.00 |
| Gross margin | — | 100.0% | — | — | — | — | — |
| R&D | $4.03M | $19.40M | $107.25M | $141.06M | $39.60M | $11.84M | $10.00M |
| SG&A | $2.56M | $14.38M | $48.31M | $62.23M | $47.55M | $44.21M | $27.22M |
| Operating income | $-6.58M | $-33.64M | $-155.56M | $-206.17M | $-159.17M | $-73.54M | $-52.91M |
| Operating margin | — | -24379.7% | — | — | — | — | — |
| EBITDA | $-6.50M | $-33.39M | $-152.81M | $-217.38M | $-147.12M | $-62.53M | $-52.37M |
| EBITDA margin | — | -24194.2% | — | — | — | — | — |
| EBIT | $-6.52M | $-33.64M | $-155.56M | $-223.37M | $-151.87M | $-66.14M | $-52.91M |
| Interest expense | $0.00 | $3.30M | $1.56M | $1.88M | $5.21M | $8.99M | $5.83M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.45M | $-37.74M | $-156.79M | $-223.18M | $-156.09M | $-74.14M | $-71.37M |
| Net income growth (YoY) | — | -484.7% | -315.5% | -42.3% | +30.1% | +52.5% | +3.7% |
| Profit margin | — | -27346.4% | — | — | — | — | — |